{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:56:31Z","timestamp":1753890991093,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972460"],"award-info":[{"award-number":["81972460"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study aimed at assessing the safety and immunogenicity of SARS-CoV-2 vaccines in patients with thyroid cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational study included thyroid cancer patients between April 1, 2021, and November 31, 2021, in the Second Affiliated Hospital of Chongqing Medical University. All participants received at least one dose of the SARS-CoV-2 vaccine. SARS-CoV-2 IgG was tested, and the interval time between the last dose and humoral response test ranged from &amp;lt;1 to 8 months. The complications after SARS-CoV-2 vaccines were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 115 participants at least received one dose of SARS-CoV-2 vaccines with a 67.0% IgG-positive rate. Among them, 98 cases had completed vaccination, and the positivity of SARS-CoV-2 IgG antibodies was 96% (24\/25) with three doses of ZF2001. SARS-CoV-2 IgG antibodies\u2019 positivity was 63.0% (46\/73) of two doses of CoronaVac or BBIBP-CorV vaccine. Additionally, after 4 months of the last-dose vaccination, the IgG-positive rate (31.6%, 6\/19) significantly decreased in thyroid cancer patients. The IgG-positive rate (81.0%, 64\/79) was satisfactory within 3 months of the last-dose vaccination. Ten (10.2%) patients had side effects after SARS-CoV-2 vaccination. Among them, two (2.0%) patients had a fever, five (5.1%) patients had injection site pain, one (1.0%) patient felt dizzy, and one patient felt dizzy and had injection site pain at the same time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. The regression time of SARS-CoV-2 IgG is significantly shorter in thyroid cancer patients than in healthy adults. Therefore, a booster vaccination dose may be earlier than the systematic strategy for thyroid cancer patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.855311","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T05:58:53Z","timestamp":1652421533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuling","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danshuang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoman","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guobing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daixing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00228-20","article-title":"Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)\/COVID-19 Detection","volume":"34","author":"Safiabadi Tali","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab361","article-title":"Effectiveness of Mrna COVID-19 Vaccines Against SARS-Cov-2 Infection in a Cohort of Healthcare\u00a0Personnel","volume":"73","author":"Swift","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102792","DOI":"10.1016\/j.jaut.2021.102792","article-title":"Mitigating Covid-19 in the Face of Emerging Virus Variants, Breakthrough Infections and Vaccine Hesitancy","volume":"127","author":"Haque","year":"2022","journal-title":"J Autoimmun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2021.12.14.21267755","DOI":"10.1101\/2021.12.14.21267755","article-title":"Mrna-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-Cov-2 Omicron Variant","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.15585\/mmwr.mm7101a4","article-title":"Risk Factors for Severe COVID-19 Outcomes Among Persons Aged \u226518 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021","volume":"71","author":"Yek","year":"2022","journal-title":"MMWR Morbid Mortal Weekly Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116063","article-title":"Covid-19 Vaccine Effectiveness in New York State","volume":"386","author":"Rosenberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and Safety of a Third Dose of Coronavac, and Immune Persistence of a Two-Dose Schedule, in Healthy Adults: Interim Results From Two Single-Centre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, BBIBP-Corv, in People Younger Than 18 Years: A Randomised, Double-Blind, Controlled, Phase 1\/2 Trial","volume":"22","author":"Xia","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 Mrna Covid-19 Vaccine Through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(21)00479-5","article-title":"Dynamic Igg Seropositivity After Rollout of Coronavac and BNT162b2 COVID-19 Vaccines in Chile: A Sentinel Surveillance Study","volume":"22","author":"Saur\u00e9","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"n2015","DOI":"10.1136\/bmj.n2015","article-title":"Effectiveness of the Coronavac Vaccine in Older Adults During a Gamma Variant Associated Epidemic of Covid-19 in Brazil: Test Negative Case-Control Study","volume":"374","author":"Ranzani","year":"2021","journal-title":"BMJ (Clin Res Ed)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and Safety of an Inactivated Whole-Virion SARS-Cov-2 Vaccine (Coronavac): Interim Results of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet (Lond Engl)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm.110907","article-title":"COVID-19 in Cancer and Non-Cancer Patients","volume":"14","author":"Taghizadeh-Hesary","year":"2021","journal-title":"Int J Cancer Manag"},{"key":"B14","doi-asserted-by":"publisher","first-page":"23294","DOI":"10.1038\/s41598-021-02692-3","article-title":"Routine COVID-19 Testing may Not be Necessary for Most Cancer Patients","volume":"11","author":"Motlagh","year":"2021","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2021.1995742","article-title":"Multicenter Study of Antibody Seroprevalence Against COVID-19 in Patients Presenting to Iranian Cancer Centers After One Year of the COVID-19 Pandemic","volume":"40","author":"Javadinia","year":"2022","journal-title":"Cancer Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm.103283","article-title":"The COVID-19 Outbreak and Oncology Centers in Iran","volume":"13","author":"Soroosh","year":"2020","journal-title":"Int J Cancer Manag"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2021.22.10.3053","article-title":"COVID-19 Vaccination and Cancer, the Need for More Data","volume":"22","author":"Javadinia","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-Cov-2 in Patients Undergoing Treatment for Cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.007","article-title":"Efficacy and Safety of BNT162b2 Vaccination in Patients With Solid Cancer Receiving Anticancer Therapy - A Single Centre Prospective Study","volume":"157","author":"Shmueli","year":"2021","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0116","article-title":"The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries","volume":"25","author":"Vaccarella","year":"2015","journal-title":"Thyroid"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00455-2","article-title":"Safety and Immunogenicity of the Vi-DT Typhoid Conjugate Vaccine in Healthy Volunteers in Nepal: An Observer-Blind, Active-Controlled, Randomised, non-Inferiority, Phase 3 Trial","volume":"22","author":"Kumar Rai","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD-Based Protein Subunit Vaccine (ZF2001) Against COVID-19 in Adults: Two Randomised, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and Immunogenicity of an Inactivated SARS-Cov-2 Vaccine, BBIBP-Corv: A Randomised, Double-Blind, Placebo-Controlled, Phase 1\/2 Trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/07357907.2021.1992420","article-title":"Immunogenicity and Safety of the Inactivated SARS-Cov-2 Vaccine (BBIBP-Corv) in Patients With Malignancy","volume":"40","author":"Ariamanesh","year":"2022","journal-title":"Cancer Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.798975","article-title":"A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-Cov-2 Vaccine (BBIBP-Corv) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome","volume":"13","author":"Joudi","year":"2022","journal-title":"Front Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-030-71697-4_6","article-title":"Sex Differences and COVID-19","volume":"1327","author":"Thomas","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex Differences in Vaccine-Induced Humoral Immunity","volume":"41","author":"Fischinger","year":"2019","journal-title":"Semin Immunopathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.855311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T05:58:56Z","timestamp":1652421536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.855311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2022.855311"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.855311","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"article-number":"855311"}}